Therapeutic AIDS Vaccines

Author(s): A. S. Bourinbaiar, R. S. Root-Bernstein, R. Abulafia-Lapid, P. G. Rytik, A. N. Kanev, V. Jirathitikal, V. G. Orlovsky

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 16 , 2006

Become EABM
Become Reviewer


Therapeutic HIV vaccines represent promising strategy as an adjunct or alternative to current antiretroviral treatment options for HIV. Unlike prophylactic AIDS vaccines designed to prevent HIV infection, therapeutic vaccines are given to already infected individuals to help fight the disease by modulating their immune response. The first immunotherapeutic trial in AIDS patients was conducted in 1983. Since then several dozen conventional therapeutic vaccine trials have been carried out. Unfortunately, the results have consistently shown that while HIV-specific immune responses were evident as a result of vaccination, the clinical improvement has been seldom observed. The instances of the apparent clinical benefit were invariably associated with unconventional vaccines that acted in accord with the principles of alloimmunization and/or autologous vaccination. All such vaccines were derived from the blood of HIV carriers or a cell culture and thus they inherently contained allo- or self-antigens unrelated to HIV. This intriguing observation raises the issue whether this clinically successful approach has been unduly neglected. The current strategy biased toward vaccines, which have shown little evidence of clinical efficacy, needs to be diversified and supplemented with research on alternative vaccine approaches geared toward immune tolerance induction.

Keywords: Alloimmunity, ARV, Autoimmunity, Autologous, HAART, Immunotherapy, Mucosa

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [2017 - 2030]
Pages: 14
DOI: 10.2174/138161206777442119
Price: $65

Article Metrics

PDF: 4